Hepatitis B Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences

Key hepatitis B companies working in the market are Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, and others.
DelveInsight's "Hepatitis B Market Insights, Epidemiology, and Market Forecast-2032 [https://www.delveinsight.com/report-store/hepatitis-b-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] report offers an in-depth understanding of the Hepatitis B, historical and forecasted epidemiology as well as the Hepatitis B market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Some of the key facts of the Hepatitis B Market Report:

*
The Hepatitis B market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

*
In September 2023, Brii Biosciences Limited announced a study of phase 2 clinical trials for PEG-IFN and BRII-835. This study will evaluate the efficacy and safety of PEG-IFN alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.

*
In September 2023, Gilead Sciences announced a study of phase 1 clinical trials for GS-2829 and GS-6779. The goal of this clinical study is to learn more about GS-2829 and GS-6779 in healthy participants and participants with CHB.

*
Key Hepatitis B Companies: Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, and Zhimeng Biopharm, and others

*
Key Hepatitis B Therapies: Bevacizumab, HB0025, ST-1898 tablets, Trovax, fruquintinib+sintilimab, Cabozantinib, AMG 102, Pazopanib, tivozanib (AV-951), Belzutifan, Temsirolimus (CCI-779), CB-839, ABT-869, Nivolumab, ABT-510/Thrombospondin-1 mimetic, bevacizumab, CP-461, and others

*
The Hepatitis B market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hepatitis B pipeline products will significantly revolutionize the Hepatitis B market dynamics.

Hepatitis B Overview

Hepatitis B is a viral infection that primarily targets the liver and is caused by the Hepatitis B virus (HBV). It represents a significant global health challenge, affecting millions of people worldwide. Hepatitis B can manifest as both an acute and a chronic infection.

**Acute Hepatitis B** is a short-term infection that lasts less than six months. Many people with acute Hepatitis B experience few or no symptoms, while others may have mild symptoms like fatigue, nausea, and jaundice (yellowing of the skin and eyes). In some cases, acute infection can lead to severe liver damage, liver failure, or even death.

**Chronic Hepatitis B** is a long-lasting infection, persisting for six months or more. Unlike the acute form, chronic Hepatitis B can last for years, causing ongoing liver inflammation and damage. This prolonged infection increases the risk of serious complications, including cirrhosis (liver scarring), liver cancer, and liver failure. However, not all individuals with chronic Hepatitis B will develop these severe outcomes.

HBV is primarily transmitted through contact with infected blood or body fluids. Common transmission routes, sharing needles or syringes, and mother-to-child transmission during childbirth. HBV is **not** spread through casual contact such as hugging, kissing, or sharing food or drinks with an infected person.

**Prevention** of Hepatitis B is most effectively achieved through vaccination. The Hepatitis B vaccine is safe and highly effective, providing protection against HBV infection. It is recommended for all infants at birth, as well as for individuals at higher risk, including healthcare workers, and those who inject drugs.

**Treatment** for Hepatitis B focuses on reducing liver inflammation, slowing liver damage, and preventing complications. Antiviral medications are commonly prescribed to suppress HBV replication and reduce the risk of liver-related complications in individuals with chronic Hepatitis B.

In summary, Hepatitis B is a serious, but preventable and treatable disease. Increased awareness, widespread vaccination, and improved access to healthcare are essential for controlling HBV transmission and improving outcomes for those affected.

Hepatitis B Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hepatitis B Epidemiology Segmentation:

The Hepatitis B market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Hepatitis B

*
Prevalent Cases of Hepatitis B by severity

*
Gender-specific Prevalence of Hepatitis B

*
Diagnosed Cases of Episodic and Chronic Hepatitis B

Download the report to understand which factors are driving Hepatitis B epidemiology trends @ Hepatitis B Epidemiology Forecast [https://www.delveinsight.com/sample-request/hepatitis-b-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Hepatitis B Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatitis B market or expected to get launched during the study period. The analysis covers Hepatitis B market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hepatitis B Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hepatitis B Key Companies

*
Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, and Zhimeng Biopharm

Hepatitis B Therapies

*
Tenofovir Alafenamidem, VIR-221, Selgantolimod, telbivudine, lamivudine, pegylated interferon-alfa 2a

Hepatitis B Market

The primary treatment for Chronic Hepatitis B currently revolves around antiviral medications, with notable options including entecavir, VEMLIDY, VIREAD, telbivudine, adefovir dipivoxil, and lamivudine. Lamivudine holds significance as the first nucleoside analogue (NA) to receive approval from the US FDA for Chronic Hepatitis B treatment. Initially approved for adults in 1998, pediatric approval for children aged 2-17 followed in 2001. Despite its initial approval for Hepatitis B, lamivudine has been utilized and licensed for HIV infection treatment since 1995. While generally well-tolerated with few side effects, prolonged lamivudine therapy is associated with significant rates of drug resistance, leading to virological relapse and biochemical flare. Consequently, lamivudine is often recommended as a second-line therapy for managing Hepatitis B.

To know more about Hepatitis B companies working in the treatment market, visit @ Hepatitis B Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/report-store/hepatitis-b-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Hepatitis B Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Hepatitis B Companies: Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, and Zhimeng Biopharm, and others

*
Key Hepatitis B Therapies: Tenofovir Alafenamidem, VIR-221, Selgantolimod, telbivudine, lamivudine, pegylated interferon-alfa 2a, and others

*
Hepatitis B Therapeutic Assessment: Hepatitis B current marketed and Hepatitis B emerging therapies

*
Hepatitis B Market Dynamics: Hepatitis B market drivers and Hepatitis B market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Hepatitis B Unmet Needs, KOL's views, Analyst's views, Hepatitis B Market Access and Reimbursement

Request for a sample pages report @ https://www.delveinsight.com/sample-request/hepatitis-b-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Table of Contents

1. Hepatitis B Market Report Introduction

2. Executive Summary for Hepatitis B

3. SWOT analysis of Hepatitis B

4. Hepatitis B Patient Share (%) Overview at a Glance

5. Hepatitis B Market Overview at a Glance

6. Hepatitis B Disease Background and Overview

7. Hepatitis B Epidemiology and Patient Population

8. Country-Specific Patient Population of Hepatitis B

9. Hepatitis B Current Treatment and Medical Practices

10. Hepatitis B Unmet Needs

11. Hepatitis B Emerging Therapies

12. Hepatitis B Market Outlook

13. Country-Wise Hepatitis B Market Analysis (2019-2032)

14. Hepatitis B Market Access and Reimbursement of Therapies

15. Hepatitis B Market Drivers

16. Hepatitis B Market Barriers

17. Hepatitis B Appendix

18. Hepatitis B Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Hepatitis B Pipeline

"Hepatitis B Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Hepatitis B market. A detailed picture of the Hepatitis B pipeline landscape is provided, which includes the disease overview and Hepatitis B treatment guidelines.

Hepatitis B Epidemiology

DelveInsight's 'Hepatitis B Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Hepatitis B epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hepatitis-b-market-report-2032-epidemiology-data-pipeline-therapies-latest-fda-ema-pdma-approvals-by-delveinsight-vedanta-biosciences-gilead-sciences-donga-st-co-assembly-biosciences]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.